Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

MET-233I

A Study of MET233 in Individuals With Obesity or Overweight

Pfizer · Phase 1 · Completed · Enrollment 144

NCT07022977

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
(Part A) MET233n/rn/rn/rn/r
(Part A) Placebon/rn/rn/rn/r
(Part B) MET233n/rn/rn/rn/r
(Part B) Placebon/rn/rn/rn/r
(Part C) MET233n/rn/rn/rn/r
(Part C) Placebon/rn/rn/rn/r
(Part D) MET233n/rn/rn/rn/r
(Part D) Placebon/rn/rn/rn/r

Not shown

  • (Part A) MET233: endpoint not reported
  • (Part A) Placebo: endpoint not reported
  • (Part B) MET233: endpoint not reported
  • (Part B) Placebo: endpoint not reported
  • (Part C) MET233: endpoint not reported
  • (Part C) Placebo: endpoint not reported
  • (Part D) MET233: endpoint not reported
  • (Part D) Placebo: endpoint not reported